Newer developments in immunohistology

Journal of Clinical Pathology

Volumn 59, Issue 11, 2006, Pages 1117-1126

  Leong, A S Y ^a,b   Leong, T Y M ^c  

^a JOHN HUNTER HOSPITAL   (Australia)

^b UNIVERSITY OF NEWCASTLE   (Australia)

^c ST VINCENT S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYLACYL COENZYME A RACEMASE; ANAPLASTIC LYMPHOMA KINASE; ANTIBODY; ANTIGEN; CD20 ANTIGEN; CD22 ANTIGEN; CD33 ANTIGEN; CETUXIMAB; COMPLEMENT COMPONENT C4D; CYCLIN DEPENDENT KINASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; GEFITINIB; GEMTUZUMAB OZOGAMICIN; IMATINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MISMATCH REPAIR PROTEIN PMS2; OCTREOTIDE; PODOPLANIN; PROTEIN BCL 10; PROTEIN KINASE ZAP 70; PROTEIN P63; RABBIT ANTISERUM; RITUXIMAB; STEM CELL FACTOR RECEPTOR; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR 3; UNCLASSIFIED DRUG; UVOMORULIN; WT1 PROTEIN;

ANTIGEN RETRIEVAL; APOPTOSIS; CANCER; CELL CYCLE; CELL PROLIFERATION; CHROMOSOME TRANSLOCATION; DIAGNOSTIC TEST; DRUG MECHANISM; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC DISORDER; GRAFT REJECTION; HUMAN; IMMUNOHISTOLOGY; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TISSUE MICROARRAY; TUMOR GROWTH;

ANTIBODIES; CELL CYCLE PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 33751208031     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.2005.031179     Document Type: Review

References (83)

1. Gatter KC, Abdulaziz Z, Beverley P, et al. Use of monoclonal antibodies for the histopathological diagnosis of human malignancy. J Clin Pathol 1982;35:1253-67.
2. Leong AS-Y, Wick MR, Swanson PE. Immunohistology and electron microscopy of anaplastic and pleomorphic tumors. Cambridge: Cambridge University Press, 1987.
3. Rossi S, Laurino L, Furlanetto A, et al. Rabbit monoclonal antibodies. A comparative study between a novel category of immunoreagents and the corresponding mouse monoclonal antibodies. Am J Clin Pathol 2005;124:295-302.
4. KIP2 immunohistochemistry. Histopathology 2003;43:363-73.
5. Kale A, Soylemez F, Ensari A. Expressions of proliferation markers (Ki-67, proliferating cell nuclear antigen, and silver-staining nucleolar organizer regions) and of p53 protein in gestational trophoblastic disease. Am J Obstet Gynecol 2001;184:567-74.
6. INK4a is a useful marker for the diagnosis or adenocarcinoma of the cervix uteri and its precursors. Am J Surg Pathol 2003;27:187-93.
7. INK4a in thin layer, liquid-based specimens. Acta Cytol 2002;46:25-9.
8. Wu HH, Lapkus O, Corbin M. Comparison of 34betaE12 and p63 in 100 consecutive prostate carcinoma diagnosed by needle biopsies. Appl Immunohistochem Mol Morphol 2004;12:285-9.
9. Barbareschi M, Pecciarini L, Giulia Cangi M, et al. p63, a p53 homologue, is a selective nuclear marker of myoepithelial cells of the human breast. Am J Surg Pathol 2001;25:1054-60.
10. Koker MM, Kleer CG. P63 expression in breast cancer: a highly sensitive and specific marker of metaplastic carcinoma. Am J Surg Pathol 2004;28:506-12.
11. Jaiswal M, LaRusso NF, Shapiro RA, et al. Nitric oxide-mediated inhibition of DNA repair potentiates oxidative DNA damage in cholangiocytes. Gastroenterology 2001;120:190-9.
12. Gasparini G, Longo R, Sarmiento R, et al. Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents? Lancet Oncol 2003;4:605-15.
13. Gown AM, Willingham MC. Improved detection of apoptotic cells in archival paraffin sections: immunohistochemistry using antibodies to cleaved caspase 3. J Immunohistochem Cytochem 2002;50:449-54.
14. Dhaene K, Van Marck E, Parwaresch R. Telomeres, telomerase and cancer: an update. Virchows Arch 2000;437:1-16.
15. Leung T-MD, Ma C-H, Niu H, et al. Nuclear telomerase is less accessible to antibody probing than known nuclear antigens: retrieval with new immunostaining buffer. Histochem Cell Biol 2005;123:105-12.
16. Jiang Z, Wu C-L, Woda, et al. P504S/α-methylacyl-CoA racemose. A useful marker for diagnosis of small foci of prostate carcinoma on needle biopsy. Am J Surg Pathol 2002;26:1169-74.
17. Jiang Z, Li C, Fischer A, et al. Using an AMACR (P504S)/34βE12/p63 cocktail for the detection of small focal prostate carcinoma in needle biopsy specimens. Am J Clin Pathol 2005;123:231-6.
18. Nassar A, Amin MB, Sexton DG, et al. Utility of alpha-methylacyl coenzyme A racemase (P504S antibody) as a diagnostic immunohistochemical marker for cancer. Appl Immunohistochem Mol Morph 2005;13:252-5.
19. Suthipintawong C, Leong AS-Y, Vinyuvat S. A comparative study of immunomarkers for lymphangiomas and hemangiomas. Appl Immunohistochem 1995;3:239-44.
20. Leong AS-Y, Cooper K, Leong FJW. Manual of diagnostic antibodies for immunohistology, 2nd edn. London: Greenwich Medical Media, 2003.
21. Kahn HJ, Bailey D, Marks A. Monoclonal antibody D2-40, a new marker of lymphatic endothelium, reacts with Kaposi's sarcoma and a subset of angiosarcomas. Mod Pathol 2002;15:434-40.
22. Fukunaga M. Expression of D2-40 in lymphatic endothelium of normal tissues and in vascular tumors. Histopatholology 2005;46:396-402.
23. Odonez NG. D2-40 and podoplanin are highly specific and sensitive immunohistochemical markers of epithelioid malignant mesothelioma. Hum Pathol 2005;36:372-80.
24. Breiteneder-Geleff S, Soleiman A, Kowalski H, et al. Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic endothelium. Am J Pathol 1999;154:385-94.
25. Browne P, Petrosyan K, Hernandez A, et al. The B cell transcription factors BSAP, Oct-2, and BOB.1 and the pan-B cell markers CD20, CD22, and CD79a are useful in the differential diagnosis of classic Hodgkin lymphoma. Am J Clin Pathol 2003;120:767-77.
26. Kreitman RJ, Squires DR, Stetler-Stevenson M, et al. Phase I trial of recombinant immunotoxin RFB4 (dsFv)-PE38*BL22) in patients with B cell malignancies. J Clin Oncol 2005;23:6719-29.
27. Nickeleit V, Zeiler M, Gudat F, et al. Detection of the complement degradation product C4d in renal allografts: diagnostic and therapeutic implications. J Am Soc Nephrol 2002;13:242-51.
28. Regele H, Bohmig GA, Habicht A, et al. Capillary deposition of complement split product C4d in renal allografts is associated with basement membrane injury in peritubular and glomerular capillaries: a contribution of humoral immunity to chronic allograft rejection. J Am Soc Nephrol 2002;13:2371-80.
29. Crespo M, Bosch F, Villamor N, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003;348:1764-75.
30. Carreras J, Villamor N, Colomo L, et al. Immunohistochemical analysis of ZAP-70 expression in B-cell lymphoid neoplasms. J Pathol 2005;205:507-13.
31. Wiestner A, Rosenwald A, Barry TS, et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmulated immunoglobulin genes, inferior clinical outcome and distinct gene expression profile. Blood 2003;101:4944-51.
32. Knosel T, Meisel H, Borgmann A, et al. Parvovirus B19 infection associated with unilateral cervical lymphadenopathy, apoptotic sinus histiocytosis, and prolonged fatigue. J Clin Pathol 2005;58:872-5.
33. Weiss RA, Whitby D, Talbot S, et al. Human herpesvirus type 8 and Kaposi's sarcoma. J Natl Cancer Inst Monogr 1998;23:51-4.
34. Barbinto-Brodano G, Sabbioni S, Martini F, et al. Simian virus 40 infection in humans and association with human diseases: results and hypotheses. Virology 2004;318:1-9.
35. Danguy A, Camby I, Kiss R. Galectins and cancer. Biochem Biophys Acta, 2002;1572:285-93.
36. Breesley MF, McLaren KM. Cytokeratin 19 and galectin-3 immunohistochemistry in the differential diagnosis of solitary thyroid nodules. Histopathology 2002;41:236-43.
37. Casey MB, Lohse CM, Lloyd RV. Distinction between papillary thyroid hyperplasia and papillary thyroid carcinoma by immunohistochemical staining for cytokeratin 19, galectin 3 and HBME1. Endocr Pathol 2003;14:55-60.
38. Sahoo S, Hoda SA, Rosai J, et al. Cytokeratin 19 immunoreactivity in the diagnosis of papillary thyroid carcinoma: a note of caution. Am J Clin Pathol 2001;116:696-702.
39. Cheung CC, Ezzat S, Freeman JL, et al. Immunohistochemical diagnosis of papillary thyroid carcinoma. Mod Pathol 2001;14:338-42.
40. Gown AM. Genogenic immunohistochemistry: a new era in diagnostic immunohistochemistry. Curr Diagn Pathol 2002;8:193-200.
41. Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 2005;23:609-18.
42. Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003;349:247-57.
43. Wood B, Leong AS-Y. Cell adhesion proteins - biology, detection and applications. Pathology 2003;35:101-5.
44. Berx G, Cleton J-AM, Strumane K, et al. E-cadherin is inactivated in a majority of human lobular breast cancer by truncation mutations throughout its extracellular domain. Oncogene 1996;13:1919-25.
45. Droufakou S, Deshmane V, Roylance R, et al. Multiple ways of silencing E-cadherin gene expression in lobular carcinoma of the breast. Int J Cancer 2001;92:404-8.
46. Keller G, Vogelsang H, Becker I, et al. Diffuse type gastric and lobular breast carcinoma in a familial cancer patient with an E-cadherin germline mutation. Am J Pathol 1999;155:337-42.
47. Graziano F, Mandolesi A, Ruzzo A, et al. Predictive and prognostic role of E-cadherin protein expression in patients with advanced gastric carcinomas treated with palliative chemotherapy. Tumour Biol 2004;25:106-10.
48. Sormunen R, Leong AS-Y, Vaaraniemi J, et al. Immunolocalisation of fodrin, E-cadherin and beta-catenin adhesion complex in infiltrating ductal carcinoma of the breast-comparison with an in vitro model. J Pathol 1999;187:416-23.
49. Yin H, Leong AS-Y. Histological grading of non-invasive papillary urothelial tumors. Validation of the 1998 WHO/ISUP system by immunophenotyping and follow-up. Am J Clin Pathol 2004;121:679-87.
50. Leong FJ, Leong AS-Y. Malignant rhabdoid tumours in adults. A unique morphologic phenotype of heterogeneous lineage differentiation. Pathol Res Pract 1996;192:796-807.
51. Medjkane S, Novikov E, Versteege I, et al. The tumor suppressor hSNF5/INI1 modulates cell growth and actin cytoskeleton organization. Cancer Res 2004;64:3406-13.
52. Perry A, Fuller CE, Judkins AR, et al. INI1 expression is retained in composite rhabdoid tumors, including rhobdoid meningiomas. Mod Pathol 2005;18:951-8.
53. Stein H, Foss HD, Durkop H, et al. CD30+ anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood 2000;96:3681-95.
54. Falini B, Bigerna B, Fizzotti M, et al. ALK expression defines a distinct group of T/null lymphomas ("ALK lymphomas") with a wide morphological spectrum. Am J Pathol 1998;153:875-86.
55. Leong AS-Y, Wick ME, Swanson P. Immunohistology and electron microscopy of anaplastic and pleomorphic tumors. Cambridge: Cambridge University Press, 1997.
56. Leong AS-Y. Immunohistology of small round cell tumors in childhood. J Histotechnol 1999;22:239-46.
57. Folpe AL, Goldblum JR, Shehata BM, et al. Morphologic and immunophenotypic diversity in Ewing family tumors: a study of 66 genetically confirmed cases. Am J Surg Pathol 2005;29:1025-33.
58. Du MQ, Isaccson PG. Gastric MALT lymphoma: from aetiology to treatment. Lancet Oncol 2002;3:97-104.
59. Hussell T, Isaacson PG, Crabtree JE, et al. Helicobacter pylori-specific tumor-infiltrating T cells provide contact dependent help for growth of malignant B cells in low-grade gastric lymphoma of mucosa-associated lymphoid tissue. J Pathol 1996;178:122-7.
60. Ye H, Gong L, Liu H, et al. MALT lymphoma with t(14;18)(q32;q21)/IgH- MALT1 is characterised by strong cytoplasmic MALT1 and Bcl10 expression. J Pathol 2005;205:293-301.
61. Isaacson PG, Du M-Q. Gastrointestinal lymphoma: where morphology meets molecular biology. J Pathol 2005;205:255-74.
62. Argani P, Lal P, Hutchinson B, et al. Aberrant nuclear immunoreactivity for TFE3 in neoplasms with TFE3 gene fusions. A sensitive and specific immunohistochemical assay. Am J Surg Pathol 2003;27:750-61.
63. Dehalle S, Blasius R, Dicato M, et al. A beginner's guide to NK-KB signalling pathways. Ann N Y Acad Sci 2004;1030:1-13.
64. Dolcet X, Llobet D, Pallares J, et al. NF-KB in development and progression of human cancer. Virch Arch 2005;446:475-82.
65. Press MF, Slamon DJ, Flom KJ, et al. Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterised cohort of breast cancer specimens. J Clin Oncol 2002;20:3095-105.
66. Yaziji H, Goldstein LC, Barry TS, et al. HER-2 testing in breast cancer using parallel tissue-based methods. JAMA 2004;291:1972-7.
67. Nowain A, Bhakta H, Pais S, et al. Gastrointestinal stromal tumors: clinical profile and pathogenesis, treatment strategies and prognosis. J Gastroenterol Hepatol 2005;20:818-24.
68. Berman J, O'Leary TJ. Gastrointestinal stromal tumor workshop. Hum Pathol. 2001;32:578-82.
69. Hernandez-Ilizaliturri FJ, Gowda A, Czuczman MS. Development of targeted therapies for B-cell non-Hodgkin lymphoma and multiple myeloma. Clin Adv Hematol Oncol 2004;2:606-18.
70. Linenberger ML. CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance. Leukemia 2005;19:176-82.
71. Goldstein NS, Armin M. Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: implications for a standardized scoring system. Cancer 2001;92:1331-46.
72. Sandler A. Clinical experience wird the HER1/EGFR tyrosine kinase inhibitor erlotinib. Oncology 2003;16(Suppl 12):17-22.
73. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomised phase II trial of gefitinib for previously treated patients with advanced non-small cell lung cancer. J Clin Oncol 2003;21:2237-46.
74. Volante M, Bozzalla-Cassione F, Papotti M. Somatostatin receptors and their interest in diagnostic pathology. Endocr Pathol 2004;15:275-91.
75. Leong AS-Y, ed. Applied Immunohistochemistry for the surgical pathologist. London: Edward Arnold, 1994:14.
76. Packeisen J, Korsching E, Herbst H, et al. Demystified ... tissue microarray technology. Mol Pathol 2003;56:198-204.
77. Leong AS-Y. Microwaves in immunohistology - the past 12 years. J Cell Patnol 1996;1:111-20.
78. Leong AS-Y, Lee ES, Yin H, et al. Antigen retrieval with controlled superheating at 120°C. Appl Immunohistochem Mol Morphol 2002;10:263-8.
79. Leong AS-Y. Microwave technology for light microscopy and ultrastructural studies. Bangkok: Amarin Printing and Publishing, 2005.
80. Sompuran SR, Vani K, Messana E, et al. A molecular mechanism of formalin fixation and antigen retrieval. Am J Clin Pathol 2004;121:190-9.
81. Leong AS-Y. Quantitation in immunohistology - fact or fiction? A discussion of factors that influence results. Appl Immunohistochem Mol Morphol 2004;12:1-7.
82. Leong AS-Y. Pitfalls in diagnostic immunohistology. Adv Anat Pathol 2004;11:86-93.
83. Leong AS-Y. Immunohistological markers for tumor prognostication. Curr Diagn Pathol 2001;7:176-86.